A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.

MLA

Boukovala, Myrto, et al. “A Candidate Androgen Signalling Signature Predictive of Response to Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer.” European Journal of Cancer (Oxford, England : 1990), vol. 127, Mar. 2020, pp. 67–75. EBSCOhost, https://doi.org/10.1016/j.ejca.2019.12.027.

APA

Boukovala, M., Spetsieris, N., Weldon, J. A., Tsikkinis, A., Hoang, A., Aparicio, A., Tu, S.-M., Araujo, J. C., Zurita, A. J., Corn, P. G., Pagliaro, L., Kim, J., Wang, J., Subudhi, S. K., Tannir, N. M., Logothetis, C. J., Troncoso, P., Wen, S., & Efstathiou, E. (2020). A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990), 127, 67–75. https://doi.org/10.1016/j.ejca.2019.12.027

Chicago

Boukovala, Myrto, Nicholas Spetsieris, Justin A Weldon, Alexandros Tsikkinis, Anh Hoang, Ana Aparicio, Shi-Ming Tu, et al. 2020. “A Candidate Androgen Signalling Signature Predictive of Response to Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer.” European Journal of Cancer (Oxford, England : 1990) 127 (March): 67–75. doi:10.1016/j.ejca.2019.12.027.